home / stock / alzn / alzn articles
Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinica...
The Dow Jones closed lower by around 388 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around ...
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-BD01, a Phase 2A st...
News, Short Squeeze, Breakout and More Instantly...
Alzamend Neuro Inc. Company Name:
ALZN Stock Symbol:
NASDAQ Market:
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...